alexa Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.
Gastroenterology

Gastroenterology

Journal of Hepatology and Gastrointestinal disorders

Author(s): Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B,

Abstract Share this page

Abstract BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic allergic disease with limited treatment options. OBJECTIVE: We evaluated QAX576, an mAb against IL-13, in the treatment of patients with EoE. METHODS: Patients (18-50 years) with proton pump inhibitor-resistant esophageal eosinophilia received intravenous QAX576 (6 mg/kg) or placebo (2:1) at weeks 0, 4, and 8 and were followed for 6 months. The primary end point was the responder rate for a greater than 75\% decrease in peak eosinophil counts at week 12. Efficacy was to be declared if the lower 90\% confidence limit for the proportion of responders on QAX576 was 35\% or greater. Secondary end points included changes in esophageal eosinophil counts, symptoms assessed by questionnaire scores, and quantification of a series of biomarkers. RESULTS: Twenty-three patients completed the study up to week 12, and 18 continued to the end of the study. For the proximal and distal esophageal biopsies combined, the responder rate was 12.5\% (90\% confidence limit, 1\% to 43\%) with placebo, compared to 40.0\% (90\% confidence limit, 22\% to 61\%) with QAX576. Although the primary end point was not met, the mean esophageal eosinophil count decreased by 60\% with QAX576 versus an increase of 23\% with placebo (P = .004), and the decrease was sustained up to 6 months. There was a trend for improved symptoms, particularly dysphagia. QAX576 improved expression of EoE-relevant esophageal transcripts, including eotaxin-3, periostin, and markers of mast cells and barrier function, for up to 6 months after treatment. QAX576 was well tolerated. CONCLUSIONS: QAX576 significantly improved intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts in adults with EoE in a sustained manner. TRIAL REGISTRATION: ClinicalTrials.gov NCT01022970. Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. This article was published in J Allergy Clin Immunol and referenced in Journal of Hepatology and Gastrointestinal disorders

Relevant Expert PPTs

Relevant Speaker PPTs

  • Dong-Kyu Kim
    Cross-Talk between Human Mast Cells and Epithelial Cells by IgE-mediated Periostin Production in Eosinophilic Nasal Polyps
    PPT Version | PDF Version
  • Etakula Nagabhushan
    Studies on the Combined Effect of Multi – Walled Carbon Nano Tubes (MWCNTs) and Maleic Anhydride grafted Polypropylene (MA – g PP) on the Mechanical and Thermal Properties of Polypropylene (PP)
    PPT Version | PDF Version
  • Diganta Kalita
    Polyphenol content and antioxidant activity of potato tubers with colored flesh: Their potential role in acrylamide formation in french fries
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords